- Home
- NMS vs BYSI Comparison
NMS vs BYSI Comparison
Compare NMS & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- BYSI
- Stock Information
- Founded
- NMS 1993
- BYSI 2010
- Country
- NMS United States
- BYSI United States
- Employees
- NMS N/A
- BYSI N/A
- Industry
- NMS Finance Companies
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- NMS Finance
- BYSI Health Care
- Exchange
- NMS Nasdaq
- BYSI Nasdaq
- Market Cap
- NMS 68.7M
- BYSI 72.1M
- IPO Year
- NMS N/A
- BYSI 2017
- Fundamental
- Price
- NMS $11.70
- BYSI $1.68
- Analyst Decision
- NMS
- BYSI
- Analyst Count
- NMS 0
- BYSI 0
- Target Price
- NMS N/A
- BYSI N/A
- AVG Volume (30 Days)
- NMS 12.0K
- BYSI 32.9K
- Earning Date
- NMS 01-01-0001
- BYSI 04-14-2022
- Dividend Yield
- NMS 4.11%
- BYSI N/A
- EPS Growth
- NMS N/A
- BYSI N/A
- EPS
- NMS N/A
- BYSI N/A
- Revenue
- NMS N/A
- BYSI N/A
- Revenue This Year
- NMS N/A
- BYSI N/A
- Revenue Next Year
- NMS N/A
- BYSI N/A
- P/E Ratio
- NMS N/A
- BYSI N/A
- Revenue Growth
- NMS N/A
- BYSI N/A
- 52 Week Low
- NMS $9.21
- BYSI $0.98
- 52 Week High
- NMS $12.18
- BYSI $3.63
- Technical
- Relative Strength Index (RSI)
- NMS 47.27
- BYSI 52.97
- Support Level
- NMS $11.43
- BYSI $1.64
- Resistance Level
- NMS $11.84
- BYSI $2.14
- Average True Range (ATR)
- NMS 0.11
- BYSI 0.18
- MACD
- NMS 0.02
- BYSI 0.03
- Stochastic Oscillator
- NMS 65.85
- BYSI 44.58
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.